US 12,220,599 B2
Wearable phototherapy apparatus with anti-viral and other effects
David Schmidt, San Diego, CA (US)
Assigned to SOLETLUNA HOLDINGS, INC., San Diego, CA (US)
Filed by SOLETLUNA HOLDINGS, INC., San Diego, CA (US)
Filed on Dec. 13, 2021, as Appl. No. 17/549,571.
Application 17/549,571 is a continuation in part of application No. PCT/US2020/035856, filed on Jun. 3, 2020.
Application PCT/US2020/035856 is a continuation in part of application No. 16/438,364, filed on Jun. 11, 2019, granted, now 10,716,953, issued on Jul. 21, 2020.
Prior Publication US 2022/0096861 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 5/06 (2006.01); A61K 33/34 (2006.01); A61K 41/00 (2020.01)
CPC A61N 5/062 (2013.01) [A61K 33/34 (2013.01); A61K 41/0057 (2013.01); A61N 5/0624 (2013.01); A61N 5/0616 (2013.01); A61N 2005/0645 (2013.01); A61N 2005/0659 (2013.01); A61N 2005/0666 (2013.01)] 17 Claims
 
1. A wearable phototherapy system configured to be applied to a subject's body to provide a beneficial effect for the subject selected from a group consisting of activation of stem cells, an improvement in energy, an elevation of antioxidants, a reduction in inflammation, an elevation of collagen production, an improvement in wound healing, an increase in strength, an increase in stamina, a relief from pain and an improvement in strength endurance, the wearable phototherapy system comprising:
a non-transdermal container configured to provide a beneficial biological effect, wherein
said non-transdermal container comprises
matter that comprises at least one Left-Handed molecule comprising at least one Left-Handed organic molecule or at least one Left-Handed inorganic molecule or both said at least one Left-Handed organic molecule and said at least one Left-Handed inorganic molecule,
wherein said at least one Left-Handed molecule further comprises a material pre-selected configured to interact with infrared light; and,
at least one phototherapy layer comprising
glycyl-L-histidyl-Lysine (GHK) or copper binding peptide glycyl-L-histidyl-Lysine (GHK-Cu) or alanyl-L-histidyl-L-Lysine (AHK) or copper binding peptide alanyl-L-histidyl-L-Lysine (AHK-Cu), or any combination thereof;
wherein, via said at least one phototherapy layer, the matter in the non-transdermal container is configured to reflect or emit specific wavelengths of light into said subject's body after said matter is stimulated by said infrared light wherein said specific wavelengths of light elevate levels of copper binding peptide glycyl-L-histidyl-Lysine (GHK-Cu) in said subject's body;
wherein the non-transdermal container is configured to prevent the at least one Left-Handed molecule from direct contact with the subject's body.